Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117125 | 0.88 | MCL1 (0.43) | MCL1PTPN1TRPV1 | |
| SCHEMBL3440742 | 0.80 | MCL1 (0.68) | MCL1PTPN1TRPV1MTNR1AMTNR1B | |
| SCHEMBL207071 | 0.79 | MTNR1A (0.48) | MTNR1AMTNR1BKDM4EMEN1RAB9A | |
| SCHEMBL25969106 | 0.75 | MCL1 (0.65) | MCL1PTPN1TRPV1MTNR1AMTNR1B | |
| SCHEMBL29349880 | 0.74 | MCL1 (1.00) | MCL1PTPN1TRPV1MTNR1AMTNR1B | |
| SCHEMBL7414597 | 0.73 | LMNA (0.39) | PTPN1MEN1MAPTRAB9AKMT2A | |
| SCHEMBL7159280 | 0.73 | MCL1 (0.61) | MCL1PTPN1TRPV1MTNR1AMTNR1B | |
| SCHEMBL6581360 | 0.72 | MCL1 (0.60) | MCL1PTPN1TRPV1MTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL7637046 | 0.72 | MCL1 (0.59) | MCL1PTPN1TRPV1MTNR1AMTNR1B | |
| SCHEMBL22804491 | 0.72 | NCEH1 (0.44) | KDM4EMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173841-B2 | Tetrahydro-naphthalene derivatives | XENTION LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| US-8088826-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl-groups; vanilloid receptor antagonists; analgesics antiinflammatory agent; urogenital disorders | XENTION LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-20110178088-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | XENTION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| EP-2048132-B1 | Tetrahydro-naphthalene and urea derivatives | XENTION LTD (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-20090209514-A1 | Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists | TAJIMI MASAOMI | 2009-08-20 | — | — | US | disclosed |
| US-7544716-B2 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | XENTION LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-20080275047-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | XENTION LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| EP-1572632-B1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS VANILLOID RECEPTOR ANTAGONISTS | XENTION LTD (GB) | 2008-08-13 | — | — | EP | disclosed |
| US-7381840-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl- group; vanilloid receptor antagonists | XENTION LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| EP-1569896-B1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-08-15 | — | — | EP | disclosed |
| US-20060135505-A1 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | BAYER HEALTHCARE AG (DE) | 2006-06-22 | — | — | US | disclosed |
| US-20060128704-A1 | Tetrahydro-naphthalene derivatives | BAYER HEALTHCARE AG (DE) | 2006-06-15 | — | — | US | disclosed |
| EP-1572632-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS VANILLOID RECEPTOR ANTAGONISTS | Bayer HealthCare AG (DE) | 2005-09-14 | — | — | EP | disclosed |
| EP-1569896-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | Bayer HealthCare AG (DE) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004052845-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS VANILLOID RECEPTOR ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052846-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135505-A1 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | OPRL1, PTGER1, LTB4R2 | MCL1 3193/4885PTPN1 1229/4885TRPV1 8/4885 |
| US-20110178088-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | OPRL1, OPRK1, VAT1 | MCL1 4125/4885PTPN1 1437/4885TRPV1 5/4885 |
| US-20060128704-A1 | Tetrahydro-naphthalene derivatives | HVCN1, HRH1, OPRL1 | MCL1 2758/4885PTPN1 1165/4885TRPV1 12/4885 |
| US-20090209514-A1 | Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists | OPRL1, TRPV1, LTB4R | MCL1 3360/4885PTPN1 1341/4885TRPV1 2/4885 |
| US-20080275047-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | TNNC1, CACNA1H, TNNI3 | MCL1 3458/4885PTPN1 960/4885TRPV1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.